# A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

> **NCT07024784** · PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 377 (estimated)

## Conditions studied

- Gynecologic Cancers
- Platinum-Sensitive Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer (PSOC)

## Interventions

- **DRUG:** IMGN151
- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT07024784
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2028-01
- **Final completion:** 2028-02
- **Target enrollment:** 377 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07024784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07024784, "A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07024784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*